Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

R 21

Next Previous
Drug Profile

R 21

Alternative Names: Malaria virus-like particle vaccine - MultiMalVax; Matrix-M; Plasmodium falciparum circumsporozoite protein/HBsAg subunit vaccine - Multimalvax; R-21; R21/Matrix-M; R21/Matrix-M adjuvanted malaria vaccine; R21/Matrix-M™ malaria vaccine; R21/MM

Latest Information Update: 20 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Oxford
  • Developer GSK; Serum Institute of India; University of Oxford
  • Class Antimalarials; Malaria vaccines; Parasitic vaccines; Subunit vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Falciparum malaria

Most Recent Events

  • 30 May 2025 PATH initiates a phase II trial for Malaria (Prevention, In Infants) in Burkina Faso (IM) (NCT06879327)
  • 06 May 2025 University of Oxford plans a phase I trial for Falciparum Malaria (Prevention, In infants, In children, In adolescents, In adults, Combination therapy) in Burkina Faso (IM, Injection) in June 2025 (NCT06958198)
  • 17 Mar 2025 PATH plans a phase II trial for Malaria (Prevention) in Burkina Faso (IM) (NCT06879327)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top